Canada’s Drug Agency | Drugs, Health Technologies and Systems.
Canada’s Drug Agency | Drugs, Health Technologies and Systems.

durvalumab, tremelimumab

Details

Files
Generic Name:
durvalumab, tremelimumab
Project Status:
Active
Therapeutic Area:
Metastatic non-small cell lung cancer (NSCLC)
Manufacturer:
AstraZeneca Canada Inc.
Call for patient/clinician input open:
Brand Name:
Imfinzi, Imjudo
Project Line:
Reimbursement Review
Project Number:
PC0390-000
Call for patient/clinician input closed:
Tumour Type:
Lung
NOC Status at Filing:
Pre NOC
Biosimilar:
No
Manufacturer Requested Reimbursement Criteria1:
Imfinzi in combination with tremelimumab and platinum-based chemotherapy is indicated for the first-line treatment of patients with metastatic NSCLC with no sensitizing epidermal growth factor receptor (EGFR) mutations or anaplastic lymphoma kinase (ALK) genomic tumour aberrations.
Submission Type:
Initial
Fee Schedule:
Schedule A
Indications:
​Imfinzi in combination with tremelimumab and platinum-based chemotherapy is indicated for the first-line treatment of patients with metastatic NSCLC with no sensitizing epidermal growth factor receptor (EGFR) mutations or anaplastic lymphoma kinase (ALK) genomic tumour aberrations.
  1. The requested reimbursement criteria are provided by the applicant and do not necessarily reflect the views of Canada's Drug Agency. Reimbursement criteria from Canada's Drug Agency will be documented in the final recommendation, if applicable.
Key Milestones2
Call for patient/clinician input openSeptember 05, 2024
Call for patient/clinician input closedOctober 28, 2024
Submission receivedOctober 17, 2024
Submission acceptedOctober 31, 2024
Review initiatedNovember 01, 2024
Draft CADTH review report(s) provided to sponsor for commentJanuary 23, 2025
Deadline for sponsors commentsFebruary 04, 2025
CADTH review report(s) and responses to comments provided to sponsorFebruary 28, 2025
Expert committee meeting (initial)March 12, 2025
Draft recommendation issued to sponsor-
Draft recommendation posted for stakeholder feedback-
End of feedback period-

Files

Patient and Clinician Group input View PDF
Last Updated : February 26, 2025